Niu FY - Search Results

1

Reduced chemotherapy sensitivity in EGFR-mutant lung cancer patient with frontline EGFR tyrosine kinase inhibitor.

Zeng Z, Yan HH, Zhang XC, Zhong WZ, He YY, Guan JL, Niu FY, Xie Z, Huang YS, Xu CR, Dong S, Wu YL. Zeng Z, et al. Among authors: niu fy. Lung Cancer. 2014 Nov;86(2):219-24. doi: 10.1016/j.lungcan.2014.09.008. Epub 2014 Sep 18. Lung Cancer. 2014. PMID: 25263853

2

Prognostic significance of genotype and number of metastatic sites in advanced non-small-cell lung cancer.

He YY, Zhang XC, Yang JJ, Niu FY, Zeng Z, Yan HH, Xu CR, Guan JL, Zhong WZ, Yang LL, Guo LH, Wu YL. He YY, et al. Among authors: niu fy. Clin Lung Cancer. 2014 Nov;15(6):441-7. doi: 10.1016/j.cllc.2014.06.006. Epub 2014 Jun 23. Clin Lung Cancer. 2014. PMID: 25044104

3

Clinical trials for lung cancer in China.

Niu FY, Zhong WZ, Zhou Q, Wu YL. Niu FY, et al. Transl Lung Cancer Res. 2014 Oct;3(5):311-6. doi: 10.3978/j.issn.2218-6751.2014.10.04. Transl Lung Cancer Res. 2014. PMID: 25806317 Free PMC article. Review.

4

Multiple primary malignancies involving lung cancer.

Li F, Zhong WZ, Niu FY, Zhao N, Yang JJ, Yan HH, Wu YL. Li F, et al. Among authors: niu fy. BMC Cancer. 2015 Oct 14;15:696. doi: 10.1186/s12885-015-1733-8. BMC Cancer. 2015. PMID: 26466785 Free PMC article.

5

Predictive and prognostic value of de novo MET expression in patients with advanced non-small-cell lung cancer.

Li A, Niu FY, Han JF, Lou NN, Yang JJ, Zhang XC, Zhou Q, Xie Z, Su J, Zhao N, Huang Y, Wu YL. Li A, et al. Among authors: niu fy. Lung Cancer. 2015 Dec;90(3):375-80. doi: 10.1016/j.lungcan.2015.10.021. Epub 2015 Nov 8. Lung Cancer. 2015. PMID: 26791795

6

Distribution and prognosis of uncommon metastases from non-small cell lung cancer.

Niu FY, Zhou Q, Yang JJ, Zhong WZ, Chen ZH, Deng W, He YY, Chen HJ, Zeng Z, Ke EE, Zhao N, Zhang N, Sun HW, Zhang QY, Xie Z, Zhang XC, Wu YL. Niu FY, et al. BMC Cancer. 2016 Feb 24;16:149. doi: 10.1186/s12885-016-2169-5. BMC Cancer. 2016. PMID: 26911831 Free PMC article.

7

A Higher Proportion of the EGFR T790M Mutation May Contribute to the Better Survival of Patients with Exon 19 Deletions Compared with Those with L858R.

Ke EE, Zhou Q, Zhang QY, Su J, Chen ZH, Zhang XC, Xu CR, Yang JJ, Tu HY, Yan HH, Zhang YC, Niu FY, Wu YL. Ke EE, et al. Among authors: niu fy. J Thorac Oncol. 2017 Sep;12(9):1368-1375. doi: 10.1016/j.jtho.2017.05.018. Epub 2017 May 30. J Thorac Oncol. 2017. PMID: 28576746 Free article.

8

The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.

Zhang Q, Ke E, Niu F, Deng W, Chen Z, Xu C, Zhang X, Zhao N, Su J, Yang J, Yan H, Wu Y, Zhou Q. Zhang Q, et al. Oncotarget. 2017 Jan 17;8(3):4994-5002. doi: 10.18632/oncotarget.14007. Oncotarget. 2017. PMID: 27999211 Free PMC article.

9

Novel agents and strategies for overcoming EGFR TKIs resistance.

Niu FY, Wu YL. Niu FY, et al. Exp Hematol Oncol. 2014 Jan 11;3(1):2. doi: 10.1186/2162-3619-3-2. Exp Hematol Oncol. 2014. PMID: 24410791 Free PMC article.

10

Personalized treatment strategies for non-small-cell lung cancer in Chinese patients: the role of crizotinib.

Niu FY, Wu YL. Niu FY, et al. Onco Targets Ther. 2015 May 2;8:999-1007. doi: 10.2147/OTT.S64664. eCollection 2015. Onco Targets Ther. 2015. PMID: 25999733 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

23 results

Search Page

Filters